A determination of pan-pathogen antimicrobials?

Baxter, 2001, Louis Pasteur's beer of revenge, Nat Rev Immunol, 1, 229, 10.1038/35105083 Strebhardt, 2008, Paul Ehrlich's magic bullet concept: 100 years of progress, Nat Rev Cancer, 8, 473, 10.1038/nrc2394 Neu, 1996, Antimicrobial Chemotherapy McNaught, 1968, Limitations of the germ theory, Lancet, 2, 220, 10.1016/S0140-6736(68)92655-X Pirofski, 2006, Immunomodulators as an antimicrobial tool, Curr Opin Microbiol, 9, 489, 10.1016/j.mib.2006.08.004 Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K, Barth S. Recent advances in immunotherapies against infectious diseases. Immunotherapy Adv. 2020:ltaa007. doi: 10.1093/immadv/ltaa007. PMCID: PMC7717302. Chitalia, 2020, A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals, J Transl Med, 18, 390, 10.1186/s12967-020-02476-9 Kelleni, 2021, Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment, SN Compr Clin Med, 3, 1, 10.1007/s42399-021-00824-4 Pathogenesis: of host and pathogen. Nat Immunol. 2006 Mar;7(3):217. doi: 10.1038/ni0306-217. PMID: 16482163. Rouse, 2010, Immunity and immunopathology to viruses: what decides the outcome?, Nat Rev Immunol, 10, 514, 10.1038/nri2802 Crua Asensio, 2017, Centrality in the host-pathogen interactome is associated with pathogen fitness during infection, Nat Commun, 16, 14092, 10.1038/ncomms14092 Portnoy, 2000, Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease, Infect Immun, 68, 6511, 10.1128/IAI.68.12.6511-6518.2000 Fischetti, 1999, Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity, Infect Immun, 67, 3703, 10.1128/IAI.67.8.3703-3713.1999 Nash, 2015, Mechanisms of cell and tissue damage, Mims' Pathogenesis Infect Dis, 171–231, 10.1016/B978-0-12-397188-3.00008-1 Sen, 2016, A review on host-pathogen interactions: classification and prediction, Eur J Clin Microbiol Infect Dis, 35, 1581, 10.1007/s10096-016-2716-7 Pitt, 2012, Classification, identification and typing of micro-organisms, Med Microbiol, 24–38, 10.1016/B978-0-7020-4089-4.00018-4 Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med. 2014;5(1):a019273. doi: 10.1101/cshperspect.a019273. PMID: 25367975; PMCID: PMC4292074. Pérez JC, Kumamoto CA, Johnson AD. Candida albicans commensalism and pathogenicity are intertwined traits directed by a tightly knit transcriptional regulatory circuit. PLoS Biol. 2013;11(3):e1001510. doi: 10.1371/journal.pbio.1001510. Epub 2013 Mar 19. PMID: 23526879; PMCID: PMC3601966. Colson, 2016, Fighting viruses with antibiotics: an overlooked path, Int J Antimicrob Agents, 48, 349, 10.1016/j.ijantimicag.2016.07.004 Casadevall, 2003, The damage-response framework of microbial pathogenesis, Nat Rev Microbiol, 1, 17, 10.1038/nrmicro732 Pirofski, 2020, Pathogenesis of COVID-19 from the perspective of the damage-response framework, mBio, 11, 10.1128/mBio.01175-20 Tauber, 2008, Immunomodulatory properties of antibiotics, Curr Mol Pharmacol, 1, 68, 10.2174/1874467210801010068 Pasquale, 2005, Nonantimicrobial effects of antibacterial agents, Clin Infect Dis, 40, 127, 10.1086/426545 Hawn, 2013, Host-directed therapeutics for tuberculosis: can we harness the host?, Microbiol Mol Biol Rev, 77, 608, 10.1128/MMBR.00032-13 Zumla, 2014, New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects, Lancet Infect Dis, 14, 327, 10.1016/S1473-3099(13)70328-1 Kaufmann, 2014, Progress in tuberculosis vaccine development and host-directed therapies–a state of the art review, Lancet Respir Med, 2, 301, 10.1016/S2213-2600(14)70033-5 Wilkinson, 2014, Host-directed therapies against tuberculosis, Lancet Respir Med, 2, 85, 10.1016/S2213-2600(13)70295-9 Chiang, 2018, Mitigating the impact of antibacterial drug resistance through host-directed therapies: current progress, outlook, and challenges, mBio, 9, 10.1128/mBio.01932-17 Tobin, 2015, Host-directed therapies for tuberculosis, Cold Spring Harb Perspect Med, 5, 10.1101/cshperspect.a021196 Heaton, 2019, Harnessing host-virus evolution in antiviral therapy and immunotherapy, Clin Transl Immunol, 8, e1067, 10.1002/cti2.1067 Duffy, 2018, Why are RNA virus mutation rates so damn high?, PLoS Biol, 16, e3000003, 10.1371/journal.pbio.3000003 Prussia A, Thepchatri P, Snyder JP, Plemper RK. Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci. 2011;12(6):4027-52. doi: 10.3390/ijms12064027. Epub 2011 Jun 15. PMID: 21747723; PMCID: PMC3131607. Estrin, 2018, Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells, PLoS ONE, 13, e0197246, 10.1371/journal.pone.0197246 Watanabe T, Kawaoka Y. [Neo-Virology: the raison d'etre of viruses]. Uirusu. 2016;66(2):155-162. Japanese. doi: 10.2222/jsv.66.155. PMID: 29081467. Wang, 2003, RNA interference: antiviral weapon and beyond, World J Gastroenterol, 9, 1657, 10.3748/wjg.v9.i8.1657 Guo, 2004, The zinc finger antiviral protein directly binds to specific viral mRNAs through the CCCH zinc finger motifs, J Virol, 78, 12781, 10.1128/JVI.78.23.12781-12787.2004 Mihara, 2016, Linking virus genomes with host taxonomy, Viruses, 8, 66, 10.3390/v8030066 Godkin, 2017, Chronic infections with viruses or parasites: breaking bad to make good, Immunology, 150, 389, 10.1111/imm.12703 Ponte-Sucre, 2017, Drug resistance and treatment failure in leishmaniasis: a 21st century challenge, PLoS Negl Trop Dis, 11, e0006052, 10.1371/journal.pntd.0006052 Lamotte, 2017, The enemy within: targeting host-parasite interaction for antileishmanial drug discovery, PLoS Negl Trop Dis, 11, e0005480, 10.1371/journal.pntd.0005480 You, 2020, Echinocandins versus amphotericin B against Candida tropicalis fungemia in adult hematological patients with neutropenia: a multicenter retrospective cohort study, Infect Drug Resist, 10, 2229, 10.2147/IDR.S258744 Sam, 2018, Immunomodulation as therapy for fungal infection: Are we closer?, Front Microbiol, 25, 1612, 10.3389/fmicb.2018.01612 Ademe, 2020, Immunomodulation for the treatment of fungal infections: opportunities and challenges, Front Cell Infect Microbiol, 15, 469, 10.3389/fcimb.2020.00469 Simitsopoulou, 2011, Immunomodulatory properties of antifungal agents on phagocytic cells, Immunol Invest, 40, 809, 10.3109/08820139.2011.615877 Alto NM, Orth K. Subversion of cell signaling by pathogens. Cold Spring Harb Perspect Biol. 2012;4(9):a006114. doi: 10.1101/cshperspect.a006114. PMID: 22952390; PMCID: PMC3428769. Pieters, 2021, Applications of omics technologies for three-dimensional in vitro disease models, Tissue Eng Part C Methods, 27, 183, 10.1089/ten.tec.2020.0300 Ling, 2020, Rhinovirus infection drives complex host airway molecular responses in children with cystic fibrosis, Front Immunol, 11, 1327, 10.3389/fimmu.2020.01327 Wang, 2009, RNA-Seq: a revolutionary tool for transcriptomics, Nat Rev Genet, 10, 57, 10.1038/nrg2484 Pattin, 2009, Role for protein-protein interaction databases in human genetics, Expert Rev Proteomics, 6, 647, 10.1586/epr.09.86 Jensen, 2020, Is it time to start transitioning from 2D to 3D cell culture?, Front Mol Biosci, 6, 33, 10.3389/fmolb.2020.00033 Mogensen, 2009, Pathogen recognition and inflammatory signaling in innate immune defenses, Clin Microbiol Rev, 22, 240, 10.1128/CMR.00046-08 Gürtler, 2013, Innate immune detection of microbial nucleic acids, Trends Microbiol, 21, 413, 10.1016/j.tim.2013.04.004 Rehwinkel, 2020, RIG-I-like receptors: their regulation and roles in RNA sensing, Nat Rev Immunol, 20, 537, 10.1038/s41577-020-0288-3 Li, 2020, When STING meets viruses: sensing, trafficking and response, Front Immunol, 11, 2064, 10.3389/fimmu.2020.02064 Marinho, 2017, The emerging roles of STING in bacterial infections, Trends Microbiol, 25, 906, 10.1016/j.tim.2017.05.008 Su, 2019, STING activation in cancer immunotherapy, Theranostics, 9, 7759, 10.7150/thno.37574 Ahn, 2019, STING signaling and host defense against microbial infection, Exp Mol Med, 51, 1, 10.1038/s12276-019-0333-0 McKnight, 2020, Stimulator of interferon genes (STING) is an essential proviral host factor for human rhinovirus species A and C, Proc Natl Acad Sci USA, 117, 27598, 10.1073/pnas.2014940117 Savigny, 2021, Protective role of the nucleic acid sensor STING in pulmonary fibrosis, Front Immunol, 11, 588799, 10.3389/fimmu.2020.588799 Welte, 2019, Azithromycin: The holy grail to prevent exacerbations in chronic respiratory disease?, Am J Respir Crit Care Med, 200, 269, 10.1164/rccm.201903-0706ED DiNicolantonio, 2020, Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion, Immunol Lett, 228, 83, 10.1016/j.imlet.2020.09.008 Braicu, 2019, A comprehensive review on MAPK: a promising therapeutic target in cancer, Cancers (Basel), 11, 1618, 10.3390/cancers11101618 Kuriakose, 2019, TLR-2 and MyD88-dependent activation of MAPK and STAT proteins regulates proinflammatory cytokine response and immunity to experimental Trypanosoma congolense Infection, Front Immunol, 10, 2673, 10.3389/fimmu.2019.02673 Sharp, 1997, The influence of the MAPK pathway on T cell lineage commitment, Immunity, 7, 609, 10.1016/S1074-7613(00)80382-9 Rincón, 2001, Signal transduction by MAP kinases in T lymphocytes, Oncogene, 20, 2490, 10.1038/sj.onc.1204382 Krachler AM, Woolery AR, Orth K. Manipulation of kinase signaling by bacterial pathogens. J Cell Biol. 2011;195(7):1083-92. doi: 10.1083/jcb.201107132. Epub 2011 Nov 28. PMID: 22123833; PMCID: PMC3246894. Kumar, 2018, Role of MAPK/MNK1 signaling in virus replication, Virus Res, 253, 48, 10.1016/j.virusres.2018.05.028 Zhanel, 2001, Review of macrolides and ketolides: focus on respiratory tract infections, Drugs, 61, 443, 10.2165/00003495-200161040-00003 Kanoh, 2010, Mechanisms of action and clinical application of macrolides as immunomodulatory medications, Clin Microbiol Rev, 23, 590, 10.1128/CMR.00078-09 Bosnar, 2011, Azithromycin inhibits macrophage interleukin-1β production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia, Int Immunopharmacol, 11, 424, 10.1016/j.intimp.2010.12.010 Yang, 2020, Mechanism of azithromycin in airway diseases, J Int Med Res, 48, 10.1177/0300060520932104 Mohanta TK, Arina P, Sharma N, Defilippi P. Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade? Am J Transl Res. 2020;12(12):7702-7708. PMID: 33437355; PMCID: PMC7791480. Singh, 2011, Nitazoxanide: a broad spectrum antimicrobial, Med J Armed Forces India, 67, 67, 10.1016/S0377-1237(11)80020-1 Shou, 2019, Tizoxanide inhibits inflammation in LPS-activated RAW264.7 macrophages via the suppression of NF-κB and MAPK activation, Inflammation, 42, 1336, 10.1007/s10753-019-00994-3 Cheng, 2017, Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line, PLoS ONE, 12, e0184324, 10.1371/journal.pone.0184324 Jiang, 2019, Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway, J Exp Clin Cancer Res, 38, 265, 10.1186/s13046-019-1251-7 Kindrachuk, 2015, Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis, Antimicrob Agents Chemother, 59, 1088, 10.1128/AAC.03659-14 DuShane, 2019, Human DNA virus exploitation of the MAPK-ERK cascade, Int J Mol Sci, 20, 3427, 10.3390/ijms20143427 Ghasemnejad-Berenji, 2021, SARS-CoV-2 and the possible role of Raf/MEK/ERK pathway in viral survival: is this a potential therapeutic strategy for COVID-19?, Pharmacology, 106, 119, 10.1159/000511280 Rochani, 2013, Heat shock protein 90 inhibitors as broad spectrum anti-infectives, Curr Pharm Des, 19, 377, 10.2174/138161213804143608 Montoya, 2018, Repurposing estrogen receptor antagonists for the treatment of infectious disease, mBio, 9, 10.1128/mBio.02272-18 Catalano, 2021, Diarylureas: Repositioning from antitumor to antimicrobials or multi-target agents against new pandemics, Antibiotics (Basel), 10, 92, 10.3390/antibiotics10010092 Levine BC. Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents. https://grantome.com/grant/NIH/U19-AI142784-01. Münz C. Beclin-1 targeting for viral immune escape. Viruses. 2011 Jul;3(7):1166-78. doi: 10.3390/v3071166. Epub 2011 Jul 12. PMID: 21994775; PMCID: PMC3185790. Sorouri, 2020, Signatures of host-pathogen evolutionary conflict reveal MISTR-A conserved mitochondrial STress response network, PLoS Biol, 18, e3001045, 10.1371/journal.pbio.3001045 Wilson, 2015, Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum, BMC Biol, 13, 52, 10.1186/s12915-015-0162-0 Kadappu, 2002, Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease, J Postgrad Med Burns, 2020, Retargeting azithromycin analogues to have dual-modality antimalarial activity, BMC Biol, 18, 133, 10.1186/s12915-020-00859-4 Hoffman, 2007, Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni, Antimicrob Agents Chemother, 51, 868, 10.1128/AAC.01159-06 Shakya, 2018, Update on nitazoxanide: a multifunctional chemotherapeutic agent, Curr Drug Discov Technol, 15, 201, 10.2174/1570163814666170727130003 Hickson, 2018, Inhibition of vaccinia virus replication by nitazoxanide, Virology, 518, 398, 10.1016/j.virol.2018.03.023 Petersen, 2016, Interferon stimulated gene expression in HIV/HCV coinfected patients treated with nitazoxanide/peginterferon-Alfa-2a and ribavirin, AIDS Res Hum Retroviruses, 32, 660, 10.1089/aid.2015.0236 Jasenosky, 2019, The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus, iScience, 19, 1279, 10.1016/j.isci.2019.07.003 Müller, 2007, A Novel giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides, Antimicrob Agents Chemother, 51, 1979, 10.1128/AAC.01548-06 Amsden, 2005, Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?, J Antimicrob Chemother, 55, 10, 10.1093/jac/dkh519 Banjanac, 2012, Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells, Pharmacol Res, 66, 357, 10.1016/j.phrs.2012.06.011 Zimmermann, 2018, The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms, Front Immunol, 9, 302, 10.3389/fimmu.2018.00302 Li, 2011, Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases, Intern Med, 50, 1663, 10.2169/internalmedicine.50.4727 Oliver, 2021, Azithromycin in viral infections, Rev Med Virol, 31, 10.1002/rmv.2163 Firth, 2021, Broad-spectrum therapeutics: a new antimicrobial class, Curr Res Pharmacol Drug Discov, 2, 100011, 10.1016/j.crphar.2020.100011 Oprea, 2015, Computational and practical aspects of drug repositioning, Assay Drug Dev Technol, 13, 299, 10.1089/adt.2015.29011.tiodrrr Gatti, 2021, Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities, Pharmaceutics, 13, 302, 10.3390/pharmaceutics13030302 Peters, 1992, A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy, Drugs, 44, 750, 10.2165/00003495-199244050-00007 Kshirsagar, 2017, Treatment of adults with acute uncomplicated malaria with azithromycin and chloroquine in India, Colombia, and Suriname, Res Rep Trop Med, 13, 85 Doan T, Hinterwirth A, Arzika AM, et al. Reduction of coronavirus burden with mass azithromycin distribution. Clin Infect Dis. 2020;ciaa606. doi:10.1093/cid/ciaa606. Online ahead of print. Kawamura, 2018, Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center, Int J Antimicrob Agents, 51, 918, 10.1016/j.ijantimicag.2018.02.009 Lee, 2017, Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial, Antiviral Res, 144, 48, 10.1016/j.antiviral.2017.05.008 Ashraf, 2018, In vitro activity of ivermectin against Staphylococcus aureus clinical isolates, Antimicrob Resist Infect Control, 7, 27, 10.1186/s13756-018-0314-4 Rajter, 2021, Use of ivermectin is associated with lower mortality in hospitalized patients with Coronavirus disease 2019, Chest, 159, 85, 10.1016/j.chest.2020.10.009 Lv, 2018, Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Res, 159, 55, 10.1016/j.antiviral.2018.09.010 Rajamuthiah, 2015, Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus, PLoS ONE, 10, e0124595, 10.1371/journal.pone.0124595 Imperi, 2013, New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa Quorum Sensing, Antimicrob Agents Chemother, 57, 996, 10.1128/AAC.01952-12 Tam, 2018, Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota, Nat Commun, 9, 5233, 10.1038/s41467-018-07705-w Kao, 2018, The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR, PLoS Negl Trop Dis, 12, e0006715, 10.1371/journal.pntd.0006715 Musher, 2006, Nitazoxanide for the treatment of Clostridium difficile colitis, Clin Infect Dis, 43, 421, 10.1086/506351 Musher, 2009, Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study, Clin Infect Dis, 48, e41, 10.1086/596552 Haffizulla, 2014, Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial, Lancet Infect Dis, 14, 609, 10.1016/S1473-3099(14)70717-0 Firth, 2020, Azithromycin: the first broad-spectrum therapeutic, Eur J Med Chem, 207, 112739, 10.1016/j.ejmech.2020.112739 Maynard, 2004, Bioterrorism: the lung under attack, Thorax, 59, 188, 10.1136/thx.2003.016659 Waterer, 2009, Bioterrorism for the respiratory physician, Respirology, 14, 5, 10.1111/j.1440-1843.2008.01446.x Yan, 2011, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, 60, 589, 10.1007/s00011-011-0307-8 Cabrita, 2019, Niclosamide repurposed for the treatment of inflammatory airway disease, JCI Insight, 4, 10.1172/jci.insight.128414 Danielsson, 2015, Antagonists of the TMEM16A calcium-activated chloride channel modulate airway smooth muscle tone and intracellular calcium, Anesthesiology, 123, 569, 10.1097/ALN.0000000000000769 Miner, 2019, Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways, Front Pharmacol, 10, 51, 10.3389/fphar.2019.00051 Hayden EC. Biodefence since 9/11: The price of protection. Nature. 2011;477(7363):150-2. 10.1038/477150a. PMID: 21900990. Hayden, 2011, Pentagon rethinks bioterror effort, Nature, 477, 380, 10.1038/477380a Fauci, 2002, Bioterrorism: defining a research agenda, Food Drug Law J, 57, 413